Skip to main content
. 2011 Jan 19;9:2. doi: 10.1186/1476-7961-9-2

Figure 1.

Figure 1

Mean expression of FcεRI prior to treatment with omalizumab. Peripheral blood was collected from the patient and a normal control subject prior to the patient's first treatment with omalizumab. Total FcεRI expression was examined in whole blood by flow cytometry using dual staining with basophil cell surface markers anti-CD123 (IL-3r) and anti-FcεRI.